Compare ARBE & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBE | XBIT |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | Israel | United States |
| Employees | 144 | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 74.4M |
| IPO Year | N/A | 2015 |
| Metric | ARBE | XBIT |
|---|---|---|
| Price | $1.11 | $2.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.38 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 20.1K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $363.94 | N/A |
| Revenue Next Year | $286.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $2.09 |
| 52 Week High | $2.88 | $3.61 |
| Indicator | ARBE | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 48.22 |
| Support Level | $0.74 | $2.35 |
| Resistance Level | $1.17 | $2.49 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 52.54 | 42.86 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.